XR2

Janam Unveils Breakthrough All-in-One UHF RFID Reader for Supply Chain Operations

Retrieved on: 
Monday, March 11, 2024
RFID, Verizon Communications, UHF, HID, SIM, Janam, Honeywell, GPS, Workflow, T-Mobile, AT&T, RAIN, XR2, EPC, Warehouse

ATLANTA, March 11, 2024 /PRNewswire/ -- MODEX 2024 – Janam Technologies, a leading provider of rugged mobile computers and contactless access solutions, today announced the launch of its XR2 UHF RFID Reader – an all-in-one device designed for real-time tracking and unprecedented visibility into the location and status of items throughout the supply chain.

Key Points: 
  • Superior sensitivity, long-range RFID reading and lightning-fast processing speeds bring enormous value to inventory management, asset tracking and other line-of-business applications.
  • XR2 is priced to deliver unparalleled value to enterprise customers that don't want to spend more than is necessary to acquire a superior, uncompromising, all-in-one UHF RFID reader.
  • By merging precise tag location information with RFID data, XR2 enables businesses to gain business-critical insights into asset logistics, streamline operations and significantly boost efficiencies across the modern supply chain.
  • "With XR2, Janam is introducing a transformative solution that will drastically improve how businesses view and manage their assets across the supply chain.

IDTechEx Explains What Apple's Vision Pro Mixed Reality Headset Does Differently

Retrieved on: 
Tuesday, June 6, 2023
Pico, Meta, IPD, Aluminium, Vive, 3D, EMagin, Eye, Lens, Media Vision Pro AudioSpectrum, Samsung, Field of view, Qualcomm, LCD, HTC, Lidar, VR, Vision, Range imaging, OLED, XR2, Top-rated United States television programs by season, MacBook Air (Apple silicon), BOE, Ecosystem, Meta Quest Pro, AR, Video game, Television, Telescopic sight, Apple

BOSTON, June 6, 2023 /PRNewswire/ -- On June 5th, Apple ended years of speculation and finally announced a mixed reality (MR) headset.

Key Points: 
  • BOSTON, June 6, 2023 /PRNewswire/ -- On June 5th, Apple ended years of speculation and finally announced a mixed reality (MR) headset.
  • The US$3499 Vision Pro headset confirmed some expectations and confounded others.
  • The Vision Pro pairs an M2 chip, also found in MacBooks, with a new R1 chip designed for processing camera and sensor feeds.
  • In summary, Apple's Vision Pro headset stands out with its custom chipset, advanced sensor and interface capabilities, innovative display choices, and premium materials.

IDTechEx Explains What Apple's Vision Pro Mixed Reality Headset Does Differently

Retrieved on: 
Tuesday, June 6, 2023
Pico, Meta, IPD, Aluminium, Vive, 3D, EMagin, Eye, Lens, Media Vision Pro AudioSpectrum, Samsung, Field of view, Qualcomm, LCD, HTC, Lidar, VR, Vision, Range imaging, OLED, XR2, Top-rated United States television programs by season, MacBook Air (Apple silicon), BOE, Ecosystem, Meta Quest Pro, AR, Video game, Television, Telescopic sight, Apple

BOSTON, June 6, 2023 /PRNewswire/ -- On June 5th, Apple ended years of speculation and finally announced a mixed reality (MR) headset.

Key Points: 
  • BOSTON, June 6, 2023 /PRNewswire/ -- On June 5th, Apple ended years of speculation and finally announced a mixed reality (MR) headset.
  • The US$3499 Vision Pro headset confirmed some expectations and confounded others.
  • The Vision Pro pairs an M2 chip, also found in MacBooks, with a new R1 chip designed for processing camera and sensor feeds.
  • In summary, Apple's Vision Pro headset stands out with its custom chipset, advanced sensor and interface capabilities, innovative display choices, and premium materials.

Thundercomm Announced Its Brand-new XR2 VR HMD and 5100 AR Glasses Solutions at CES 2023

Retrieved on: 
Monday, January 9, 2023
Technology, Other Technology, Software, Fashion, Hardware, Retail, IOT (Internet of Things), Artificial Intelligence, Consumer Electronics, Imagination, Ecosystem, PC, OS, USB, HMD, CES, XR2, Growth, AI, AR, Android, VR, MP, Linux, Internet, OEM, IOT, RGB, Voice recognition, Video game console, XR, Qualcomm

Thundercomm , the world-leading IoT product and solution provider, unveiled its Qualcomm Snapdragon XR2 platform based VR HMD solution and Qualcomm Snapdragon W5 platform based AR glasses solution at CES 2023.

Key Points: 
  • Thundercomm , the world-leading IoT product and solution provider, unveiled its Qualcomm Snapdragon XR2 platform based VR HMD solution and Qualcomm Snapdragon W5 platform based AR glasses solution at CES 2023.
  • The new XR2 VR HMD solution and 5100 AR glasses solution unlock most of the advanced features of AR/VR glasses to make them an ideal platform for building next-generation AR and VR glasses, featuring low-power consumption, higher resolution, voice recognition and more comfortable to wear.
  • Thundercomm all-in-one XR2 VR HMD features 4 x camera based 6DoF head tracking and can support 6DoF controller.
  • 5100 AR glasses bring Thundercomm learnings of low power consumption, low memory usage, fast boot and OS optimization into one highly-integrated, compact and lightweight AR glasses reference design, which can handle voice recognition and translation.

Pharvaris to Present PHVS416 and PHVS719 Clinical Data for Treatment of HAE at the ACAAI Annual Scientific Meeting 2022

Retrieved on: 
Thursday, November 10, 2022
Investor, ACAAI, GLOBE, Plasma, Fasting, Intellectual property, U.S. Securities and Exchange Commission, FDA, Pharmacokinetics, Food, Hereditary angioedema, Colon, Neck pain, HAE, EC50, Annual report, Safety, XR2, Time, Union, Attack, Gastrointestinal tract, Human, Absorption, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Degenerative disease, Security (finance), Food and Drug Administration Amendments Act of 2007, Industry, COVID-19, American College, Pharmaceutical industry, Vaccine

The data presented at ACAAI demonstrate the optimized pharmacokinetic and tolerability profiles of Pharvaris drug candidates that are in clinical development for the treatment of HAE, said Peng Lu, M.D., Ph.D., Chief Medical Officer of Pharvaris.

Key Points: 
  • The data presented at ACAAI demonstrate the optimized pharmacokinetic and tolerability profiles of Pharvaris drug candidates that are in clinical development for the treatment of HAE, said Peng Lu, M.D., Ph.D., Chief Medical Officer of Pharvaris.
  • Presentation details and key data highlights include:
    Pharmacokinetic properties of PHA121 were evaluated to support the intended therapeutic use of PHVS719 for the prophylactic treatment of HAE attacks using preclinical and clinical experimental models.
  • Together, these data support clinical development of the extended-release tablet PHVS719 as a once-daily prophylactic treatment of HAE attacks.
  • PHVS416 is currently in Phase 2 clinical development outside the U.S. for the on-demand and proof-of-concept prophylactic treatment of HAE.

Omnicell Unveils Innovative IVX Station Robotic Compounding Technology in Winter 2022 Release

Retrieved on: 
Tuesday, March 29, 2022
Health, Medical Devices, Technology, Hospitals, Other Technology, Pharmaceutical, Hardware, Spend, Private Securities Litigation Reform Act, Substance-related disorder, Overalls, Hospital, Prescription, Technology, Pharmacist, Goal, Nasdaq, Solution, Annual report, University, IV, Pharmacy, Population, Cyberattack, XT, IVX, Institute, U.S. Securities and Exchange Commission, Patient safety, Pharmacy technician, Temperature, Benchmarking, Robotics, Investment, OMCL, Forward-looking statement, University of Rochester Medical Center, Program, Intelligence, Health, EHR, Adoption, Approximation error, Automation, United Kingdom, XR2, Compliance, XTS-400, Safety, MSBA, COVID-19, Risk management, Medical device, Renewable energy, Omnicell

This innovative solution is designed to scale the benefits of leveraging IV robotic technology, making it accessible to the mainstream market.

Key Points: 
  • This innovative solution is designed to scale the benefits of leveraging IV robotic technology, making it accessible to the mainstream market.
  • Omnicells Winter 2022 Release introduces new technology and enhancements to existing solutions that are expected to add value for customers.
  • IVX Station is available through Omnicells IV Compounding Service, which combines the technology with expertly trained pharmacy technicians and services in an effort to ensure value realization.
  • OMNICELL and the Omnicell logo are registered trademarks and Omnicell One is a trademark of Omnicell, Inc. or one of its subsidiaries.

Tucson VA Medical Center Selects Omnicell’s Central Pharmacy Dispensing Service to Enhance Medication Inventory Management

Retrieved on: 
Tuesday, November 2, 2021
Software, Contracts, Pharmaceutical, Data Management, Technology, White House, Federal Government, State, Local, Hospitals, Defense, Practice Management, Other Technology, Health, Public Policy, Government, Safety, Pharmacy, Veteran, Benchmarking, Compliance, Efficiency, Automation, Technology, Patient safety, Industry, United States Department of Veterans Affairs, Partnership, Veterans Health Administration, Patient, Private Securities Litigation Reform Act, Pharmacist, U.S. Securities and Exchange Commission, Administration, Prescription, Intelligence, Annual report, Forward-looking statement, United Kingdom, Approximation error, OMCL, CPDS, Solution, Nasdaq, Health, Population, XR2, Hospital

Omnicell, Inc. (Nasdaq: OMCL) (Omnicell or the Company), a leading provider of medication management solutions and adherence tools for health systems and pharmacies, today announced that Tucson VA Medical Center has chosen the Companys Central Pharmacy Dispensing Service (CPDS) in an effort to enhance patient safety, improve operational efficiency, and optimize inventory management for its central pharmacy operations.

Key Points: 
  • Omnicell, Inc. (Nasdaq: OMCL) (Omnicell or the Company), a leading provider of medication management solutions and adherence tools for health systems and pharmacies, today announced that Tucson VA Medical Center has chosen the Companys Central Pharmacy Dispensing Service (CPDS) in an effort to enhance patient safety, improve operational efficiency, and optimize inventory management for its central pharmacy operations.
  • Arizona-based Tucson VA Medical Center will expand its Omnicell platform with the Companys CPDS which includes the XR2 robotic pharmacy dispensing technology, operational staff, maintenance support, and embedded intelligence for real-time insights.
  • Tucson VA Medical Center is the first Veterans Administration facility to adopt this comprehensive as-a-service model that should help improve pharmacy operations, enhance patient safety, reduce medication waste, and enable the reallocation of high value clinical resources from frustrating manual tasks to direct patient care.
  • Omnicells CPDS supports this vision by automating critical workflows to empower pharmacy staff to focus on patients rather than administrative tasks.